Expert opinion paper on the treatment of hemophilia A with emicizumab

References

• Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801–1809. DOI:10.1016/S0140-6736(03)13405-8.
   PubMed Web of Science ®Google Scholar
• Castaman G, Matino D. Hemophilia A and B: molecular and clinical similarities and differences. Haematologica. 2019;104:1702–1709. DOI:10.3324/haematol.2019.221093.
   PubMed Web of Science ®Google Scholar
• Okaygoun D, Oliveira DD, Soman S, et al. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28:64. DOI:10.1186/s12929-021-00760-4.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377:809–818. DOI:10.1056/NEJMoa1703068.
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134:2127–2138. DOI:10.1182/blood.2019001869.
   PubMed Web of Science ®Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379:811–822. DOI:10.1056/NEJMoa1803550.
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6:e295–e305. DOI:10.1016/S2352-3026(19)30054-7.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18:1570–1574. DOI:10.1038/nm.2942.
   PubMed Web of Science ®Google Scholar
• Samelson-Jones BJ, Guelcher C, Kuhn J, et al. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. 2021;27:591–598. DOI:10.1111/hae.14347.
   PubMed Web of Science ®Google Scholar
• Callaghan MU, Negrier C, Paz-Priel I, et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021;137:2231–2242. DOI:10.1182/blood.2020009217.
   PubMed Web of Science ®Google Scholar
• Shima M, Nogami K, Nagami S, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 2019;25:979–987. DOI:10.1111/hae.13848.
   PubMed Web of Science ®Google Scholar
• McCary I, Guelcher C, Kuhn J, et al. Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia. 2020;26:631–636. DOI:10.1111/hae.14005.
   PubMed Web of Science ®Google Scholar
• Barg AA, Livnat T, Budnik I, et al. Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br J Haematol. 2020;191:282–290. DOI:10.1111/bjh.16964.
   PubMed Web of Science ®Google Scholar
• Barg AA, Budnik I, Avishai E, et al. Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring. Haemophilia. 2021;27:383–391. DOI:10.1111/hae.14318.
   PubMed Web of Science ®Google Scholar
• Warren BB, Chan A, Manco-Johnson M, et al. Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: a single-center report. Res Pract Thromb Haemost. 2021;5; DOI:10.1002/rth2.12571.
   PubMed Web of Science ®Google Scholar
• Wall C, Xiang H, Palmer B P, et al. Efficacy and safety of emicizumab prophylaxis in severe haemophilia A without inhibitors: a report from the UK Haemophilia Centre Doctors’ Organisation (UKHCDO) [abstract]. Res Pr. Thromb Haemost. 2021;5(Supp 2):388–389.
   Google Scholar
• Buckner TW, Rapacchietta O, Hill D, et al. Improved prophylaxis adherence after switching to emicizumab: real-world data from a single center [abstract]. Res Pr. Thromb Haemost. 2020;4(Supp 1).
   Google Scholar
• Santagostino E, Oldenburg J, Chang T, et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors [abstract]. Res Pr Thromb Haemost. 2019;3(Supp 3):115.
   Google Scholar
• Coppola A, Castaman G, Santoro RC, et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020;26:937–945. DOI:10.1111/hae.14172.
   PubMed Web of Science ®Google Scholar
• Collins PW, Quon DVK, Makris M, et al. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia. 2018;24:104–112. DOI:10.1111/hae.13324.
   PubMed Web of Science ®Google Scholar
• Escuriola-Ettingshausen C, Auerswald G, Königs C, et al. Optimizing the management of patients with haemophilia A and inhibitors in the era of emicizumab: recommendations from a German expert panel. Haemophilia. 2021;27; DOI:10.1111/hae.14010.
   PubMed Web of Science ®Google Scholar
• Kizilocak H, Marquez-Casas E, Malvar J, et al. Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia. 2022. DOI:10.1111/hae.14684
   PubMed Web of Science ®Google Scholar
• Barg AA, Avishai E, Budnik I, et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors – a single-center cohort. Pediatr Blood Cancer. 2019;66; DOI:10.1002/pbc.27886.
   PubMed Web of Science ®Google Scholar
• Lewandowska M, Randall N, Bakeer N, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US. Haemophilia. 2021;27:90–99. DOI:10.1111/hae.14212.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26:1–158. DOI:10.1111/hae.14046.
   PubMed Web of Science ®Google Scholar
• Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935–1939. DOI:10.1111/jth.12672.
   PubMed Web of Science ®Google Scholar
• Wyseure T, Mosnier LO, von Drygalski A. Advances and challenges in hemophilic arthropathy. Semin Hematol. 2016;53:10–19. DOI:10.1053/j.seminhematol.2015.10.005.
   PubMed Web of Science ®Google Scholar
• Castro FA, Silkey M, O’Hara J, et al. Joint bleeds in paediatric patients with haemophilia A: a CHESS study analysis [abstract]. Res Pr Thromb Haemost. 2019;3(Supp 1)):121–122.
   PubMedGoogle Scholar
• Kiialainen A, Niggli M, Kempton CL, et al. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 2022;28:1033–1043. DOI:10.1111/hae.14642.
   PubMedGoogle Scholar
• Skinner MW, Négrier C, Paz-Priel I, et al. The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021;27:854–865. DOI:10.1111/hae.14363.
   PubMed Web of Science ®Google Scholar
• Conway JH. Initial presentations of pediatric hemophiliacs. Arch Pediatr Adolesc Med. 1994;148:589. DOI:10.1001/archpedi.1994.02170060043007.
   PubMedGoogle Scholar
• Ljung R, Petrini P, Nilsson IM. Diagnostic symptoms of severe and moderate haemophilia A and B A survey of 140 cases. Acta Paediatr. 1990;79:196–200. DOI:10.1111/j.1651-2227.1990.tb11438.x.
   PubMed Web of Science ®Google Scholar
• Thornburg CD. How I approach: previously untreated patients with severe congenital hemophilia A. Pediatr Blood Cancer. 2018;65:e27466. DOI:10.1002/pbc.27466.
   PubMed Web of Science ®Google Scholar
• Stieltjes N, Calvez T, Demiguel V, et al. Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death. Haemophilia. 2005;11:452–458. DOI:10.1111/j.1365-2516.2005.01090.x.
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Alamelu J, Collins PW, et al. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015: A national cohort study. Haemophilia. 2018;24:641–647. DOI:10.1111/hae.13461.
   PubMed Web of Science ®Google Scholar
• Young G. Management of children with hemophilia A: how emicizumab has changed the landscape. J Thromb Haemost. 2021;19:1629–1637. DOI:10.1111/jth.15342.
   PubMed Web of Science ®Google Scholar
• Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost. 2019;119:1084–1093. DOI:10.1055/s-0039-1688687.
   PubMed Web of Science ®Google Scholar
• Bowyer AE, Lowe AE, Tiefenbacher S. Laboratory issues in gene therapy and emicizumab. Haemophilia. 2021;27:142–147. DOI:10.1111/hae.13976.
   PubMed Web of Science ®Google Scholar
• Shinohara S, Saito T, Noguchi-Sasaki M, et al. Evaluation of emicizumab calibrator and controls with a modified one-stage FVIII assay on an automated coagulation analyzer [abstract]. Res Pr Thromb Haemost. 2019;3(Suppl. 1).
   Google Scholar
• Wilmot EH, Hogwood J, Williams S, et al. Laboratory measurement of emicizumab requires a product specific calibrator. Res Pr Thromb Haemost. 2019;3(Suppl. 1).
   Google Scholar
• Franchini M, Marano G, Veropalumbo E, et al. Patient blood management: a revolutionary approach to transfusion medicine. Blood Transfus. 2019;17:191–195. DOI:10.2450/2019.0109-19.
   PubMed Web of Science ®Google Scholar
• McCormick A. Laboratory monitoring of emicizumab in treated patients – how does APTT compare? Res Pr. Thromb Haemost. 2021;5(Suppl. 2).
   Google Scholar
• Jenkins PV, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020;26:151–155. DOI:10.1111/hae.13903.
   PubMed Web of Science ®Google Scholar
• Kizilocak H, Yukhtman CL, Marquez-Casas E, et al. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019;10; DOI:10.1177/2040620719860025.
   PubMed Web of Science ®Google Scholar
• Yada K, Nogami K, Ogiwara K, et al. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol. 2019;110:419–430. DOI:10.1007/s12185-019-02698-8.
   PubMed Web of Science ®Google Scholar
• Levy-Mendelovich S, Brutman-Barazani T, Budnik I, et al. Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab. J Clin Med. 2021;10:4303. DOI:10.3390/jcm10194303.
   PubMed Web of Science ®Google Scholar
• Mason JA, Young G. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: illustrative real-world cases to support shared decision-making. Haemophilia. 2021;27:724–729. DOI:10.1111/hae.14353.
   PubMedGoogle Scholar
• Cohen CT, Diaz R. Emicizumab in pediatric hemophilia: bleeding and surgical outcomes from a single-center retrospective study. Pediatr Blood Cancer. 2021;68; DOI:10.1002/pbc.29325.
   Web of Science ®Google Scholar
• Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia. 2021;27; DOI:10.1111/hae.14432.
   Google Scholar